As part of its ongoing efforts to ensure the safe use of medications and improve communication with all segments of society, the Saudi Food and Drug Authority (SFDA) has indicated that it received over 173,000 reports of drug side effects during the first half of 2024. To enhance health safety for all citizens and residents in the Kingdom of Saudi Arabia, the SFDA made this announcement. The reports were submitted through official reporting channels from various regions across the Kingdom.

The CEO of the Saudi Food and Drug Authority (SFDA), Dr. Hisham bin Saad Aljadhey, held a meeting today with several CEOs from local and international pharmaceutical companies at the SFDA headquarters in Riyadh. The discussions focused on strengthening cooperation and collaboration, exploring strategies to align with the objectives of Saudi Vision 2030, particularly in developing national industries and advancing the SFDA's fourth strategic plan, which prioritizes product safety and aims to enhance product availability.

The Saudi Food and Drug Authority (SFDA) declared violations against six pharmaceutical facilities that either failed to have the registered products available for the local market or didn’t report on an expected shortage or interruption in supply.
The SFDA clarified that its inspectors monitored the violating facilities during continuous monitoring and inspection visits in July. The SFDA pointed out that it imposed penalties and financial fines exceeding SAR 121,000, in accordance with the Pharmaceutical and Herbal Facilities and Products Law and its Implementing Regulation.

The Saudi Food & Drug Authority (SFDA) announced that the abstract submission for Research Day 2024 is still open. The event will take place on Sunday, October 27, 2024, at the SFDA headquarters.

Abstracts should align with the SFDA Research Day 2024 theme and cover topics related to human drugs, veterinary drugs, herbal products, food, feed, pesticides, medical devices and supplies, cosmetics, and tobacco.